Related Experiment Video

Updated: Jun 7, 2026

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers
10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers

Published on: September 26, 2019

Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy

L M Wang1, D M Ren

  • 1The Department of Natural Products Chemistry, School of Pharmaceutical Science, Shandong University, 44 Wenhua Xi Road, Ji'nan 250012, Shandong Province, China.

Mini Reviews in Medicinal Chemistry
|November 5, 2010
PubMed

Insights

Flavopiridol, a cyclin-dependent kinase inhibitor (CDKI), shows potential in cancer treatment by blocking cell proliferation and inducing cell death. It also enhances chemotherapy effectiveness when used in combination therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cell cycle regulation is crucial for cell division; its dysregulation is linked to cancer development.
  • Cyclin-dependent kinases (CDKs) are key regulators of the cell cycle and represent important cancer targets.
  • Cyclin-dependent kinase inhibitors (CDKIs) are a novel class of chemotherapeutic agents.

Purpose of the Study:

  • To review the role of flavopiridol, the first CDKI in clinical trials, in cancer therapy.
  • To explore flavopiridol's efficacy as a single agent and in combination with other chemotherapeutic agents.
  • To highlight emerging data on flavopiridol's potentiating effects in combination therapies.

Main Methods:

  • Review of preclinical data on flavopiridol's effects on neoplastic cell proliferation and apoptosis.
  • Analysis of emerging clinical and preclinical data on flavopiridol in combination with established chemotherapeutic agents.
  • Focus on dose- and sequence-dependent effects of flavopiridol in combination regimens.

Main Results:

  • Flavopiridol demonstrates potential as a single agent by inhibiting cancer cell proliferation and inducing programmed cell death.
  • Flavopiridol can enhance the anti-tumor effects of various chemotherapeutic agents.
  • These potentiating effects are generally dependent on the dose and sequence of administration.

Conclusions:

  • Flavopiridol is a promising CDKI with demonstrated anti-cancer activity.
  • Combination therapy with flavopiridol and established agents warrants further investigation for improved cancer treatment outcomes.
  • The dose- and sequence-dependent nature of flavopiridol's effects necessitates careful consideration in therapeutic strategies.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...